RT info:eu-repo/semantics/article
T1 Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders
A1 Olivé-Cirera, Gemma
A1 Fonseca, Elianet
A1 Cantarín-Extremera, Verónica
A1 Vázquez-López, María
A1 Jiménez-Legido, María
A1 González-Álvarez, Verónica
A1 Ribeiro-Constante, Juliana
A1 Camacho-Salas, Ana
A1 Martí, Itxaso
A1 Martínez-González, María Jesús
A1 Saiz, Albert
A1 Armangué, Thaís
AB Background and Objectives To investigate whether children receiving immunosuppressive therapies for neuroimmunologic disorders had (1) increased susceptibility to SARS-CoV2 infection or to develop more severe forms of COVID-19; (2) increased relapses or autoimmune complications if infected; and (3)changes in health care delivery during the pandemic.Methods Patients with and without immunosuppressive treatment were recruited to participate in aretrospective survey evaluating the period from March 14, 2020, to March 30, 2021. Demographics, clinical features, type of immunosuppressive treatment, suspected or confirmed COVID-19 in the patients or cohabitants, and changes in care delivery were recorded.Results One hundred fifty-three children were included: 84 (55%) female, median age 13 years(interquartile range [8–16] years), 79 (52%) on immunosuppressive treatment. COVID-19was suspected or confirmed in 17 (11%) (all mild), with a frequency similar in patients with andwithout immunosuppressive treatment (11/79 [14%] vs 6/74 [8%], p = 0.3085). The frequency of neurologic relapses was similar in patients with (18%) and without (21%) COVID19. Factors associated with COVID-19 included having cohabitants with COVID-19 (p <0.001) and lower blood levels of vitamin D (p = 0.039). Return to face-to-face schooling or mask type did not influence the risk of infection, although 43(28%) children had contact with a classmate with COVID-19. Clinic visits changed from face to face to remote for 120 (79%) patients; 110 (92%) were satisfied with the change.Discussion In this cohort of children with neuroimmunologic disorders, the frequency of COVID-19 waslow and not affected by immunosuppressive therapies. The main risk factors for developing COVID-19 were having cohabitants with COVID-19 and low vitamin D levels
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/64718
UL https://uvadoc.uva.es/handle/10324/64718
LA spa
NO Neurology Neuroimmunollogy & Neuroinflammation 2021 Jan 10;9(1):e1101
DS UVaDOC
RD 25-nov-2024